We are live on ! Find out more
BLRX

BioLineRX
BLRX

24 hedge funds and large institutions have $5.65M invested in BioLineRX in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less funds holding

Funds holding: 26 → 24 (-2)

22% less capital invested

Capital invested by funds: $7.28M → $5.65M (-$1.63M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$48.1K
2
UBS Group
UBS Group
Switzerland
+$31.9K
3
ARTA
A.R.T. Advisors
New York
+$24.1K
4
CCB
Cutter & Co Brokerage
Missouri
+$23.5K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$11.8K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$99K
2
Millennium Management
Millennium Management
New York
-$69.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$40K
4
PAG
Private Advisor Group
New Jersey
-$15K
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAG
26
Private Advisor Group
New Jersey
– -$15K -25 Closed
PNC Financial Services Group
27
PNC Financial Services Group
Pennsylvania
– -$10K -17 Closed
Citigroup
28
Citigroup
New York
– -$1K -2 Closed
1
2

BLRX Hedge Fund Activity: Q2 2016 in Review

24 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2016, worth a combined $5.65M — down 22% from $7.28M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BLRX and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $48.1K. The largest seller was Virtu KCG Holdings, cutting an estimated $99K.

  • 24 institutional investors held BioLineRX (BLRX) as of Q2 2016, down from 26 in Q1 2016.
  • Funds reported $5.65M of BioLineRX stock for Q2 2016, down 22% quarter-over-quarter.
  • 2 funds opened new BioLineRX positions in Q2 2016 and 4 closed out, a net change of -2 holders.
  • The largest BioLineRX buyer in Q2 2016 was Morgan Stanley, an estimated $48.1K added.
  • The largest BioLineRX seller in Q2 2016 was Virtu KCG Holdings, an estimated $99K sold.

Based on aggregated 13F filings for Q2 2016.